Nevertheless, several phase I clinical trials (NCT05622058, NCT03725436, NCT03654716) of ALRN-6924 in patients with TP53 breast cancer and in combination with paclitaxel, a naturally occurring antineoplastic agent, to treat whom in advanced, metastatic, or unresectable solid tumors are still ongoing. Here, TP53 is linked to breast cancer.